In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
CTS transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and ...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...